These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32353632)

  • 21. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
    Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
    Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
    Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
    Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
    Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
    [No Abstract]   [Full Text] [Related]  

  • 26. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Gainor JF; Dardaei L; Yoda S; Friboulet L; Leshchiner I; Katayama R; Dagogo-Jack I; Gadgeel S; Schultz K; Singh M; Chin E; Parks M; Lee D; DiCecca RH; Lockerman E; Huynh T; Logan J; Ritterhouse LL; Le LP; Muniappan A; Digumarthy S; Channick C; Keyes C; Getz G; Dias-Santagata D; Heist RS; Lennerz J; Sequist LV; Benes CH; Iafrate AJ; Mino-Kenudson M; Engelman JA; Shaw AT
    Cancer Discov; 2016 Oct; 6(10):1118-1133. PubMed ID: 27432227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
    Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Katayama R
    Cancer Sci; 2018 Mar; 109(3):572-580. PubMed ID: 29336091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
    Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
    Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.
    Yun MR; Choi HM; Lee YW; Joo HS; Park CW; Choi JW; Kim DH; Kang HN; Pyo KH; Shin EJ; Shim HS; Soo RA; Yang JC; Lee SS; Chang H; Kim MH; Hong MH; Kim HR; Cho BC
    EMBO Mol Med; 2019 Dec; 11(12):e10581. PubMed ID: 31633304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.
    Katayama R
    Pharmacol Ther; 2017 Sep; 177():1-8. PubMed ID: 28185914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.